In the April 13, 2007, issue of Science, the research team—led by James C. Lo, an MD, PhD student, in the laboratory of Yang-Xin Fu, MD, PhD, professor of pathology at the University of Chicago—suggest that an engineered protein could keep mice, and possibly humans, from developing high cholesterol and triglyceride levels, a key risk factor for coronary heart disease.
"Besides showing a link between the immune system and elevated lipids, this study also opens a new avenue for the study of the close and complex link between elevated blood lipid levels and chronic inflammation as manifest in coronary heart disease, ," said Fu, senior author on the paper. "It reveals a quite unexpected role of hepatic T cells in lipid metabolism."
"Those with inflammatory problems such as lupus, rheumatoid arthritis and inflammatory bowel syndrome have a higher incidence of cardiovascular disease, often associated with elevated lipid levels," added co-author Godfrey Getz, MD, PhD, professor of pathology, biochemistry and molecular biology at the University of Chicago. "This study may explain why. The next step would be to determine whether we can use this technique to manipulate the immune response and have a favorable impact on lipid metabolism."
Using an assortment of engineered and non-engineered mice, the researchers looked specifically at the role of T cells (white blood cells that play a key role in immunity). They determined that altering the expression level of LIGHT (a specific type of molecule that binds to a receptor site of another cell) and also lymphotoxin (LT) on T cells significantly impacted the cholesterol and triglyceride levels.
Source:University of Chicago Medical Center